AbCellera Biologics (ABCL) Other Non-Current Liabilities (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Other Non-Current Liabilities data on file, last reported at $11.3 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 597.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 597.11% YoY) and the FY2025 annual result came in at $13.9 million, up 93.65% from the prior year.
• Other Non-Current Liabilities eased to $11.3 million in Q1 2026, from $13.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $30.6 million in Q1 2022 to a low of $1.4 million in Q3 2025.
• A 5-year average of $7.1 million and a median of $4.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities slumped 75.43% — and 2026, when it jumped 597.11%.
• Tracing ABCL's Other Non-Current Liabilities over 5 years: stood at $3.1 million in 2022, then jumped by 59.2% to $4.9 million in 2023, then jumped by 45.92% to $7.2 million in 2024, then soared by 93.65% to $13.9 million in 2025, then retreated by 18.45% to $11.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $11.3 million (Q1 2026), $13.9 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.